Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Ramosetron, Aprepitant and Dexamethasone (RAD) in Solid Cancer (RAD)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2012 by Hallym University Medical Center.
Recruitment status was:  Active, not recruiting
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Hallym University Medical Center
ClinicalTrials.gov Identifier:
NCT01046461
First received: January 8, 2010
Last updated: February 16, 2012
Last verified: February 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: June 2012
  Estimated Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)